These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 28027027)

  • 61. Sociodemographic factors, prescription history and opioid overdose deaths: a statewide analysis using linked PDMP and mortality data.
    Nechuta SJ; Tyndall BD; Mukhopadhyay S; McPheeters ML
    Drug Alcohol Depend; 2018 Sep; 190():62-71. PubMed ID: 29981943
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Modeling the Dynamics of Heroin and Illicit Opioid Use Disorder, Treatment, and Recovery.
    Cole S; Wirkus S
    Bull Math Biol; 2022 Mar; 84(4):48. PubMed ID: 35237877
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Risk factors for heroin use following release from jail or prison in adults in a Central Appalachian state between 2012-2017.
    Smith KE; Archuleta A; Staton M; Winston E
    Am J Drug Alcohol Abuse; 2020; 46(4):485-497. PubMed ID: 33223579
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Trends in opioid initiation among people who use opioids in three US cities.
    Rouhani S; Park JN; Morales KB; Green TC; Sherman SG
    Drug Alcohol Rev; 2020 May; 39(4):375-383. PubMed ID: 32249463
    [TBL] [Abstract][Full Text] [Related]  

  • 65. The OPTIMA study, buprenorphine/naloxone and methadone models of care for the treatment of prescription opioid use disorder: Study design and rationale.
    Socias ME; Ahamad K; Le Foll B; Lim R; Bruneau J; Fischer B; Wild TC; Wood E; Jutras-Aswad D
    Contemp Clin Trials; 2018 Jun; 69():21-27. PubMed ID: 29627621
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Association between jail-based methadone or buprenorphine treatment for opioid use disorder and overdose mortality after release from New York City jails 2011-17.
    Lim S; Cherian T; Katyal M; Goldfeld KS; McDonald R; Wiewel E; Khan M; Krawczyk N; Braunstein S; Murphy SM; Jalali A; Jeng PJ; MacDonald R; Lee JD
    Addiction; 2023 Mar; 118(3):459-467. PubMed ID: 36305669
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Racial and ethnic differences in opioid agonist treatment for opioid use disorder in a U.S. national sample.
    Krawczyk N; Feder KA; Fingerhood MI; Saloner B
    Drug Alcohol Depend; 2017 Sep; 178():512-518. PubMed ID: 28719885
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Barriers and facilitators to the use of medication for opioid use disorder within the criminal justice system: Perspectives from clinicians.
    Booty MD; Harp K; Batty E; Knudsen HK; Staton M; Oser CB
    J Subst Use Addict Treat; 2023 Jun; 149():209051. PubMed ID: 37084815
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Inequities in access to primary care among opioid recipients in Ontario, Canada: A population-based cohort study.
    Gomes T; Campbell TJ; Martins D; Paterson JM; Robertson L; Juurlink DN; Mamdani M; Glazier RH
    PLoS Med; 2021 Jun; 18(6):e1003631. PubMed ID: 34061846
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Health and economic outcomes of treatment with extended-release naltrexone among pre-release prisoners with opioid use disorder (HOPPER): protocol for an evaluation of two randomized effectiveness trials.
    Murphy SM; Jeng PJ; Poole SA; Jalali A; Vocci FJ; Gordon MS; Woody GE; Polsky D
    Addict Sci Clin Pract; 2020 Apr; 15(1):15. PubMed ID: 32321570
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Medications for opioid use disorder among pregnant women referred by criminal justice agencies before and after Medicaid expansion: A retrospective study of admissions to treatment centers in the United States.
    Winkelman TNA; Ford BR; Shlafer RJ; McWilliams A; Admon LK; Patrick SW
    PLoS Med; 2020 May; 17(5):e1003119. PubMed ID: 32421717
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Impact of a jail-based treatment decision-making intervention on post-release initiation of medications for opioid use disorder.
    Banta-Green CJ; Williams JR; Sears JM; Floyd AS; Tsui JI; Hoeft TJ
    Drug Alcohol Depend; 2020 Feb; 207():107799. PubMed ID: 31865058
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Stigma and policy preference toward individuals who transition from prescription opioids to heroin.
    Goodyear K; Chavanne D
    Addict Behav; 2021 Apr; 115():106784. PubMed ID: 33360280
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Integrating injectable opioid agonist treatment into a drug treatment court program: A case study.
    Jun JH; Fairbairn N
    Subst Abus; 2018; 39(4):493-496. PubMed ID: 29949453
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Opioid Misuse and Associated Health Risks among Adults on Probation and Parole: Prevalence and Correlates 2015-2020.
    Morrison M; Hai AH; Bandaru YS; Salas-Wright CP; Vaughn MG
    Subst Use Misuse; 2024; 59(1):20-28. PubMed ID: 37735916
    [TBL] [Abstract][Full Text] [Related]  

  • 76. High risk and little knowledge: overdose experiences and knowledge among young adult nonmedical prescription opioid users.
    Frank D; Mateu-Gelabert P; Guarino H; Bennett A; Wendel T; Jessell L; Teper A
    Int J Drug Policy; 2015 Jan; 26(1):84-91. PubMed ID: 25151334
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Transition from nonmedical prescribed opioids to non-injection heroin use among young integrated Thai male users in Bangkok.
    Hawangchu D; Rene Lamy F; Stephan Felix M; Phukao D
    J Ethn Subst Abuse; 2022 Oct; ():1-27. PubMed ID: 36190323
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Opioid analgesics and heroin: Examining drug misuse trends among a sample of drug treatment clients in Kentucky.
    Victor GA; Walker R; Cole J; Logan TK
    Int J Drug Policy; 2017 Aug; 46():1-6. PubMed ID: 28511053
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Postoperative opioid misuse in patients with opioid use disorders maintained on opioid agonist treatment.
    Namiranian K; Siglin J; Sorkin JD; Norris EJ; Aghevli M; Covington EC
    J Subst Abuse Treat; 2020 Feb; 109():8-13. PubMed ID: 31856954
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Medicaid Coverage of Methadone Maintenance and the Use of Opioid Agonist Therapy Among Pregnant Women in Specialty Treatment.
    Bachhuber MA; Mehta PK; Faherty LJ; Saloner B
    Med Care; 2017 Dec; 55(12):985-990. PubMed ID: 29135769
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.